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Introduction
The FUT2 (fucosyltransferase 2) gene encodes the alpha (1,2) 
fucosyltransferase, which determines blood group secretor status. 
About 20% of Caucasians are homozygous for the nonsense 
mutation W143X (rs601338G>A), encoding a stop codon that 
inactivates the FUT2 enzyme1. Individuals who are homozygous 
for this “non-secretor” allele (AA) are unable to secrete histo- 
blood group antigens into bodily fluids, or express them on 
mucosal surfaces.
Non-secretors have a lower risk of diarrheal illness2 and ear 
infections in childhood3. The non-secretor phenotype also con-
fers resistance to specific pathogens that require FUT2-dependent 
antigens to infect host cells, including Norovirus4–7, Rotavirus8–11 
and Helicobacter pylori12,13. By contrast, the non-secretor phe-
notype has been associated with increased susceptibility to other 
pathogens, including Candida14–16, Haemophilius influenza17, 
Neisseria meningitis18 and Streptococcus pneumonia18. Most 
recently, in a genome-wide association study (GWAS) of com-
mon infections, Tian et al. reported an increased susceptibility 
to mumps in non-secretors3. In addition, non-secretors appear 
to be at increased risk for certain autoimmune diseases, includ-
ing type 1 diabetes19, psoriasis20,21 and inflammatory bowel 
disease22,23.
The above associations have not been simultaneously examined 
in a single population and several have not been independently 
replicated. Moreover, the association of FUT2 secretor status 
with other infectious and chronic diseases has not been widely 
studied. Finally, previous studies have typically only considered 
the secretor phenotype as dichotomous, assuming the non- 
secretor allele to be recessive. In this study, we characterized the 
association of FUT2 secretor status with a variety of infectious 
and chronic diseases in the population-based Avon Longitudinal 
Study of Parents and Children (ALSPAC), and examined the 
impact of heterozygosity for the non-secretor allele.
Methods
Study design and population
This study accessed data from the ALSPAC cohort. ALSPAC 
recruited 14,541 pregnant women (98% Caucasian) resident in 
the former county of Avon, UK with expected dates of delivery 
1st April 1991 to 31st December 199224,25. The current analysis 
included a subset of 7,582 Caucasian women who selected and 
provided written informed consent for genotyping analysis, and 
reported their personal medical history during pregnancy. ABO 
blood group was collected from clinical records for the major-
ity of participants (N=6,757). The ALSPAC website contains 
details of all the data that is available through a fully search-
able data dictionary at http://www.bris.ac.uk/alspac/research-
ers/data-access/data-dictionary/. Ethical approval for the study 
was obtained from the ALSPAC Ethics and Law Committee and 
the Local Research Ethics Committees.
Genotyping
ALSPAC mothers were genotyped using the Illumina 
human660W-quad array at Centre National de Génotypage 
(CNG) (Evry, France) and genotypes were called with Illumina 
GenomeStudio. PLINK (v1.07) was used to carry out quality 
control (QC) measures on an initial set of 10,015 participants and 
557,124 directly genotyped single nucleotide polymorphisms 
(SNPs). SNPs were removed if they displayed more than 5% miss-
ingness or a Hardy-Weinberg equilibrium P value of less than 
1.0×10−6. Additionally, SNPs with a minor allele frequency of less 
than 1% were removed. Samples were excluded if they displayed 
more than 5% missingness, had indeterminate X chromosome 
heterozygosity or extreme autosomal heterozygosity. Samples 
showing evidence of population stratification were identified by 
multidimensional scaling of genome-wide identity by state pair-
wise distances using the four HapMap populations as a refer-
ence, and then excluded26. Cryptic relatedness was assessed 
using an identity by descent (IBD) estimate of more than 0.125, 
which is expected to correspond to roughly 12.5% alleles shared 
IBD or relatedness at the first cousin level. Related partici-
pants that passed all other QC thresholds were retained during 
subsequent phasing and imputation. In total, 9,048 mothers and 
526,688 SNPs passed these QC filters.
Imputation
A total of 477,482 SNP genotypes in common between the sam-
ple of mothers described above and a second sample of 9,115 
children were combined. SNPs with genotype missingness above 
1% due to poor quality (N=11,396 SNPs) were removed and a 
further 321 participants were removed due to potential ID 
mismatches. This resulted in a dataset of 17,842 participants, 
containing 6,305 duos and 465,740 SNPs (112 were removed 
during liftover and 234 were out of HWE after combination). 
Haplotypes were estimated using ShapeIT (v2.r644), which 
utilizes relatedness during phasing. The phased haplotypes were 
then imputed to the Haplotype Reference Consortium (HRC) 
panel of approximately 31,000 phased whole genomes using 
Impute V3. For this study, we excluded the mothers who had 
removed consent, leaving 8,698 eligible mothers. We further 
excluded those who did not provide personal medical history, 
leaving 7,582 for analysis.
Exposure: FUT2 genotype
FUT2 secretor status was defined based on the rs601338 SNP1, 
where G is the wild-type “secretor” allele and A is the nonsense 
W143X “non-secretor” allele. Following previous studies7,11,19,23, 
we considered the A allele to be recessive and dichotomized 
secretor status, combining the GA and GG genotypes as secre-
tors and comparing them to the homozygous AA non-secretors. 
In addition, we explored the impact of GA heterozygosity at this 
locus. Two other commonly reported non-secretor alleles 
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were considered. The missense variant at rs1047781, described 
in Asian populations27 was not detected in our Caucasian pop-
ulation. The non-synonymous S258G variant at rs60266228 
was highly correlated with rs601338; incorporating this 
SNP to define secretor status had no impact on 98% of 
participants’ phenotype classification, and did not materially 
change our results.
Outcomes: infections and chronic conditions
Infections and chronic conditions were self-reported using a 
standardized questionnaire during pregnancy. Women were asked 
if they had ever had various infections (measles, mumps, chicken 
pox, whooping cough, cold sores, meningitis, genital herpes, 
gonorrhea and urinary infections) or chronic conditions (diabetes, 
hypertension, kidney disease, rheumatism, arthritis, psoriasis, 
hay fever, asthma, eczema, and any allergies, including cat, dust, 
pollen, insect bites or ‘other’).
Statistical analysis
Demographic characteristics were summarized with descriptive 
statistics and compared between non-secretors (AA) and secre-
tors (GA or GG combined) using t-tests for continuous variables 
or chi-squared tests for categorical variables. For each outcome, 
the relative risk (RR) and 95% confidence interval (95% CI) was 
calculated for non-secretors versus secretors. A multivariable 
model was used to determine whether the association of FUT2 
secretor status and kidney disease was independent of measles, 
mumps and urinary tract infections. Multivariable models 
were also used to mutually adjust for FUT2 secretor status and 
ABO blood group and to formally test for interaction between 
these two factors. To explore the potential impact of FUT2 
heterozygosity, a three group analysis was also conducted, 
considering the AA, GA and GG genotypes separately and using 
homozygous secretors (GG) as the reference group. All statistical 
analyses were performed in SAS (version 9.4, Carey, NC, US).
Results
Overall, 1920 women were homozygous for the FUT2 non- 
secretor allele (AA, 25.3%), 1906 were homozygous for the 
secretor allele (GG, 25.1%) and 3756 were heterozygous 
(GA, 49.5%). Almost half (46%) were first-time mothers, 21% 
were unmarried, 21% smoked, and 14% had a university degree. 
The mean (± standard deviation) age was 26.9 (± 5.9) years 
and the mean body mass index was 22.9 (± 3.7) kg/m2. These 
demographic characteristics were not associated with FUT2 
secretor status (Table 1). The lifetime incidence of infections 
ranged from <1% for meningitis to 87% for chicken pox, while 
the incidence of chronic conditions ranged from 1% for 
diabetes to 43% for allergies.
Dichotomous FUT2 secretor status and infections
The homozygous AA non-secretor genotype was associated 
with mumps infection, with 68% of non-secretors experienc-
ing this infection, compared to 48% of secretors (RR, 1.40; 95% 
CI, 1.34–1.46; p<0.0001) (Table 2). Weaker associations were 
observed for measles infection (76% vs. 72%; RR, 1.05; 95% 
CI, 1.02–1.09; p=0.0008) and urinary infections (57% vs. 55%; 
RR, 1.05; 95% CI, 1.00–1.10; p=0.05). There was no strong 
evidence of association between FUT2 secretor status and 











Age, years 26.9 ± 5.9 26.9 ± 5.8 0.94
BMI, kg/m2 22.8 ± 3.6 23.0 ± 3.7 0.05
Married
    No 423 (22.4) 1173 (21.2) 0.28
    Yes 1468 (77.6) 4364 (78.8)
Parity
    0 861 (46.3) 2539 (46.2) 0.67
    1 641 (34.4) 1957 (35.6)
    2 264 (14.2) 738 (13.4)
    3 or more 95 (5.1) 259 (4.7)
Smoking
    No 1480 (78.8) 4324 (77.9) 0.37
    Yes 397 (21.2) 1229 (22.1)
Education
    <O level 457 (24.6) 1418 (25.8) 0.44
    O level 642 (34.5) 1946 (35.4)
    A level 461 (24.8) 1306 (23.8)
    University degree 276 (14.8) 762 (13.9)
Values are mean ± standard deviation or n (%). AA, homozygous for non-
secretor alleles; GG, homozygous for secretor alleles; GA, heterozygous; 
ALSPAC, Avon Longitudinal Study of Parents and Children; BMI, body 
mass index. Comparisons by t-test for continuous variables or chi-squared 
test for categorical variables.
Dichotomous FUT2 secretor status and chronic conditions
Homozygous AA non-secretors experienced a 39% increased 
risk of self-reported kidney disease compared to secretors (5.4% 
vs. 3.9%; RR, 1.39; 95% CI, 1.11–1.75; p=0.004) (Table 2). This 
association was essentially unchanged in a multivariable model 
controlling for mumps, measles and urinary infections (adjusted 
RR, 1.39; 95% CI, 1.10–1.75; p=0.005). Directionally consistent 
results were also observed for diabetes (RR, 1.23; 95% CI, 
0.76–2.00; p=0.40), rheumatism (RR 1.19, 95%CI: 0.94–1.51, 
p=0.14) and arthritis (RR, 1.21; 95% CI, 0.93–1.57; p=0.15), 
although power was lacking for these relatively rare out-
comes. There was no strong evidence of association between 
FUT2 secretor status and hypertension, hay fever, asthma or 
allergies (Table 2).
ABO blood group
Since secretor status determines the ability to secrete blood 
group antigens, we also explored the impact of ABO blood group 
on associations observed for mumps infection and kidney dis-
ease (Table 3). For both conditions, the effect estimate for FUT2 
secretor status was essentially unchanged following adjustment 
for ABO blood group and there was no significant interaction 
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cases (%) cases (%) RR (95% CI)
Infections
    measles 1458 (75.9) 4076 (72.0) 1.05 (1.02, 1.09) 0.0008 
    mumps 1299 (67.7) 2734 (48.3) 1.40 (1.34, 1.46) <0.0001 
    chicken pox 1656 (86.3) 4925 (87.0) 0.99 (0.97, 1.01) 0.41
    whooping cough 222 (11.6) 638 (11.3) 1.03 (0.89, 1.18) 0.73
    cold sores 843 (43.9) 2458 (43.4) 1.01 (0.95, 1.07) 0.71
    meningitis 15 (0.8) 61 (1.1) 0.73 (0.41, 1.27) 0.26
    genital herpes 45 (2.3) 108 (1.9) 1.23 (0.87, 1.73) 0.24
    gonorrhea 29 (1.5) 70 (1.2) 1.22 (0.80, 1.88) 0.36
    urinary infection 1095 (57.0) 3085 (54.5) 1.05 (1.00, 1.10) 0.05 
Chronic conditions
    kidney disease 103 (5.4) 218 (3.9) 1.39 (1.11, 1.75) 0.004 
    hypertension 272 (14.2) 804 (14.2) 1.00 (0.88, 1.13) 0.94
    diabetes 23 (1.2) 55 (1.0) 1.23 (0.76, 2.00) 0.40
    rheumatism 93 (4.8) 230 (4.1) 1.19 (0.94, 1.51) 0.14
    arthritis 77 (4.0) 188 (3.3) 1.21 (0.93, 1.57) 0.15
    psoriasis 59 (3.1) 213 (3.8) 0.82 (0.62, 1.08) 0.16
    hay fever 573 (29.8) 1742 (30.8) 0.97 (0.90, 1.05) 0.45
    asthma 215 (11.2) 652 (11.5) 0.97 (0.84, 1.12) 0.71
    eczema 469 (24.4) 1271 (22.4) 1.09 (0.99, 1.19) 0.07
    any allergies 837 (43.6) 2412 (42.6) 1.02 (0.97, 1.09) 0.42
AA, homozygous for non-secretor alleles; GG, homozygous for secretor alleles; GA, heterozygous; 
ALSPAC, Avon Longitudinal Study of Parents and Children; RR, relative risk; CI, confidence interval. 




n/N % RR (95% CI) p n/N % RR (95% CI) p
FUT2 Genotype
   Non-Secretor (AA) 1299/1920 67.7 1.39 (1.33, 1.46) <.0001 103/1920 5.4 1.32 (1.04, 1.69) 0.02
   Secretor (AG or GG) 2734/5662 48.3 1.00 (ref) 218/5662 3.9 1.00 (ref)
Blood Group
   A 1522/2917 52.2 1.00 (0.95, 1.05) 0.93 135/2917 4.6 1.09 (0.56, 2.11) 0.14
   B 316/608 52.0 0.99 (0.91, 1.07) 0.78 26/608 4.3 1.10 (0.73, 1.67) 0.64
   O 1595/3015 52.9 1.00 (ref) 117/3015 3.9 1.00 (ref)
   AB 129/217 59.4 1.15 (1.03, 1.28) 0.01 9/217 4.1 1.09 (0.56, 2.11) 0.80
RR, relative risk; CI, confidence interval. Models are mutually adjusted for FUT2 genotype and blood group.
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Figure 1. Relative risk of (A) infectious and (B) chronic conditions among 7,582 mothers in the ALSPAC cohort according to FUT2 genotype 
at rs601338.
between FUT2 and ABO blood group (p for interaction: 0.60 
for mumps, 0.57 for kidney disease). Independent of FUT2 
secretor status, women with type AB blood had an increased 
risk of mumps infection (59.4%) compared to women with type 
A, B, or O blood (52.2%, 52.0%, 52.9%, respectively; adjusted 
RR 1.15, 95% CI: 1.03, 1.28 for AB vs O, p=0.01). ABO 
blood group was not associated with kidney disease.
FUT2 heterozygosity
Compared to homozygous GG secretors, GA heterozygotes 
experienced a similar risk of mumps infection (RR, 0.97; 95% 
CI, 0.91–1.02; p=0.24) and kidney disease (RR, 0.99; 95% 
CI, 0.75–1.30; p=0.93), suggesting that increased susceptibility to 
these conditions (as described above) is likely to be a recessive 
trait experienced only in homozygous AA non-secretors. Similar 
evidence was found for measles, urinary infections and eczema, 
where disease risk was comparable for individuals with GG and 
GA genotypes. However, this pattern was not consistent across 
all conditions. For example, the risk of asthma was similarly 
reduced in GA heterozygotes (11.1%) and AA non-secretors 
(11.2%) compared to GG secretors (12.2%), and the risk of 
arthritis was lower in GA heterozygotes (3.0%) compared to 
either homozygous genotype (4.0% in AA, 3.8% in GG), although 
statistical evidence of association was weak for these relatively 
rare outcomes (Figure 1).
Discussion
Our findings from the population-based ALSPAC cohort confirm 
and extend previous research associating the FUT2 genotype 
with susceptibility to infections and chronic diseases. Specifi-
cally, we confirmed a recently reported association with mumps 
infection3 and identified an association with self-reported kidney 
disease. We also evaluated a number of other common condi-
tions (e.g. whooping cough, chicken pox and asthma) but found 
no strong evidence of association with FUT2 secretor status, 
indicating that FUT2 influences pathogen- or disease-specific 
processes, rather than overall innate or adaptive immunity. 
Finally, our results suggest that FUT2 heterozygosity may 
confer an intermediate phenotype for certain conditions, although 
further research is required to replicate these findings.
Our results confirm the association reported in a recent GWAS 
for common infections among 23andMe research participants 
by Tian et al.3, where the FUT2 rs516316(C) allele was associ-
ated with mumps infection (odds ratio, 1.25; 95% CI, 1.24–1.27). 
This risk allele is in complete linkage disequilibrium with the 
non-secretor rs601338(A) allele evaluated in our study, where 
a strong association was also observed (RR, 1.40; 95% CI, 
1.34–1.46). Tian et al. hypothesized that non-secretors are more 
susceptible to mumps infection because binding of the mumps 
virus to host cell sialic acid receptors is enhanced in the absence 
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of FUT2-dependent antigens on the cell surface. Indeed, using 
x-ray crystallography and functional assays, Kubota et al.29 
recently showed that mumps virus preferentially uses a trisac-
charide containing α2,3-linked sialic acid in unbranched sugar 
chains as a receptor. Our results provide further evidence that 
susceptibility to mumps infection is modulated by FUT2 secretor 
status.
Tian et al.3 also reported an association between the ABO gene 
and mumps infection, and suggested that ABO antigens may 
disrupt binding of the mumps virus to host cell receptors. Our 
results using clinical ABO blood group data support and extend 
this finding by confirming an association and specifically identi-
fying blood type AB as a risk factor for mumps infection. Since 
FUT2 secretor status determines whether ABO antigens are 
secreted into body fluids and onto cell surfaces, we hypothesized 
that secretor status and blood type may interact to influence 
susceptibility to mumps infection; however, we found no 
evidence of this interaction. Thus, our study suggests that FUT2 
genotype and ABO blood group are independently associated 
with mumps infection, with increased risk among non-secretors 
and blood type AB. 
Our study also provides new evidence that non-secretors may be 
predisposed to kidney disease (RR, 1.39; 95% CI, 1.11–1.75), 
although we lacked clinical information to confirm and clas-
sify this self-reported diagnosis. To our knowledge, the FUT2 
genotype has not previously been associated with kidney 
disease in the general population, although some studies have 
used traditional blood group assays to evaluate secretor status 
in patients with pyelonephritis (kidney inflammation, typically 
due to bacterial infection). One study of women with acute 
uncomplicated pyelonephritis found that non-secretor status was 
significantly more common in these patients than in the general 
population30, and another found that renal scarring in girls with 
recurrent pyelonephritis was more common in non-secretors 
than secretors31. It has been hypothesized that these asso-
ciations reflect an increased susceptibility to uropathogenic 
Escherichia coli infection among non-secretors, resulting 
from the enhanced expression of preferred binding recep-
tors in the vaginal epithelium and kidneys of non-secretor 
women32,33. Notably, in our study, the association between FUT2 
genotype and self-reported kidney disease appeared to be inde-
pendent of self-reported urinary infections. However, there are 
multiple clinically-distinct causes of “kidney disease” and 
“urinary infections”, and we lacked clinical information to 
define the etiology of these conditions in our study. Thus, 
additional research is needed to replicate our observations with 
confirmed and clinically-defined kidney disease and urinary 
infections, and to examine the possible relationship between 
these conditions and FUT2 genotype.  
Consistent with previous studies19–21, we observed a trend 
towards an increased risk of arthritis, rheumatism and diabetes 
among non-secretors, although we lacked statistical power for the 
analysis of these relatively uncommon autoimmune disorders.
Finally, we examined disease risk among GA heterozygotes, 
who are typically considered secretors because the non-secretor 
rs601338(A) allele is assumed to be recessive. Our results for 
mumps and kidney disease support this assumption, as increased 
susceptibility was only seen in homozygous AA non-secretors. 
However, we observed different patterns of association for 
some other conditions, including a potentially increased risk of 
gonorrhea and reduced risk of arthritis among GA heterozy-
gotes, although our effect estimates were imprecise for these 
relatively rare conditions. Further research is warranted to repli-
cate these observations in larger populations, and explore whether 
heterozygosity may impart an intermediate risk or unique 
protection from certain conditions.
Limitations of this work include the reliance on self-reported 
medical histories and low power for rare outcomes (such as 
meningitis, diabetes and other autoimmune diseases). Power 
was also limited for interaction analyses. Also, we could not 
identify the specific pathogens responsible for urinary infections, 
and we lacked clinical data to confirm, classify and define the 
etiology of multifactorial disorders (such as allergies and kidney 
disease).  Finally, our analysis of the ALSPAC pregnancy cohort 
was limited to women, so the results may not be generalizable to 
men, and potential sex differences could not be investigated.
In conclusion, our results identify a novel association between 
FUT2 non-secretor status and increased risk of kidney disease, 
and confirm a recently-reported association with increased 
susceptibility to mumps infection. The clinical implications of 
these associations warrant further investigation.
Data availability
The ALSPAC data management plan (http://www.bristol.
ac.uk/alspac/researchers/data-access/documents/alspac-data-
management-plan.pdf) describes in detail the policy regarding 
data sharing, which is through a system of managed open 
access. The steps below highlight how to apply for access to 
the data included in this paper and all other ALSPAC data. 
The datasets used in this analysis are linked to ALSPAC project 
number B3047; please quote this project number during your 
application.
1.  Please read the ALSPAC access policy (PDF, 627kB)
which describes the process of accessing the data and
samples in detail, and outlines the costs associated with
doing so.
2.  You may also find it useful to browse the fully search-
able ALSPAC research proposals database, which lists
all research projects that have been approved since
April 2011.
3.  Please submit your research proposal for consideration
by the ALSPAC Executive Committee. You will receive a
response within 10 working days to advise you whether
your proposal has been approved.
If you have any questions about accessing data, please email 
alspac-data@bristol.ac.uk.
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We agree that it would be ideal to access clinical data to confirm and further classify
these self-reported diagnoses. Unfortunately, clinical data are not available. We have
added “self-reported” ahead of “kidney disease” in the results and discussion, and we
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 these self-reported diagnoses. Unfortunately, clinical data are not available. We have
added “self-reported” ahead of “kidney disease” in the results and discussion, and we
have expanded and reworded the discussion of these results and related limitations











Thank you for this suggestion. We have repeated our analysis accounting for these two
alternative mutations, and the results are essentially unchanged. This is not surprising
because:
The rs1047781A>T mutation is only observed in Asian populations. As expected, it
was not observed in our Caucasian population.
The rs602662G>A mutation is highly correlated with the main rs601338 mutation
that we have already analyzed. Accounting for this mutation identified an additional
155 non-secretors; the secretor status of the remaining 7427 individuals (98%) did
not change.
 
We have now mentioned in the Methods section: “Two other commonly reported
non-secretor alleles were considered. The missense variant at rs1047781, described in
Asian populations (Ferrer et al. 2009)) was not detected in our Caucasian population. The
non-synonymous S258G variant at rs602662 (Barret et al. 2008) was highly correlated with
rs601338; incorporating this SNP to define secretor status had no impact on 98% of





HapMap was used because the analysis of population stratification was completed for the
ALSPAC cohort before 1000 Genomes data were available. HapMap is adequate for
checking overt ancestry as part of genotyping cleaning, especially because the ALSPAC
cohort is 98% Caucasian, and genetic analyses were restricted to Caucasians (this
information has now been added to the Methods). We have now cited the 2004 paper that
describes this analysis (Pembrey et al. https://www.ncbi.nlm.nih.gov/pubmed/15554897).
Note that for SNP imputation, which was completed more recently, we used the Haplotype
 Reference Consortium, which is even more fine-scale than 1000 Genomes.
 We have no competing interests to disclose.Competing Interests:
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Thank you for your comments, Dr. Le Pendu. Please see our pont-by-point responses
below in bold.









Thank you for these positive remarks. 
 
Specific comments:





Thank you for this suggestion. We have now incorporated clinical blood group data in our
analysis. This is described in the Methods, Results (new Table 3) and Discussion:
 
(METHODS) “ABO blood group was collected from clinical records for the majority of
participants (N=6,757).” and “Multivariable models were also used to mutually adjust for
FUT2 secretor status and ABO blood group and to formally test for interaction between
these two factors.”
1
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 these two factors.”
(RESULTS) “Since secretor status determines the ability to secrete blood group antigens,
we also explored the impact of ABO blood group on associations observed for mumps
infection and kidney disease (SEE NEW TABLE 3: Mutually-adjusted associations of FUT2
secretor status and ABO blood group with mumps infection and kidney disease in the
). For both conditions, the effect estimate for FUT2 secretor status wasALSPAC cohort
essentially unchanged following adjustment for ABO blood group and there was no
evidence of interaction between FUT2 and ABO blood group (p for interaction: 0.60 for
mumps, 0.57 for kidney disease). Independent of FUT2 secretor status, women with type
AB blood had an increased risk of mumps infection (59.4%) compared to women with type
A, B, or O blood (52.2%, 52.0%, 52.9%, respectively; adjusted RR 1.15, 95% CI: 1.03, 1.28
for AB vs O, p=0.01). ABO blood group was not associated with kidney disease.”
 
(DISCUSSION) “Tian et al. also reported an association between the ABO gene and
mumps infection, and suggested that ABO antigens may disrupt binding of the mumps
virus to host cell receptors. Our results using clinical ABO blood group data support and
extend this finding by confirming an association and specifically identifying blood type AB
as a risk factor for mumps infection. Since FUT2 secretor status determines whether ABO
antigens are secreted into body fluids and onto cell surfaces, we hypothesized that
secretor status and blood type may interact to influence susceptibility to mumps
infection; however, we found no evidence of this interaction. Thus, our study suggests
that FUT2 genotype and ABO blood group are independently associated with mumps
infection, with increased risk among non-secretors and blood type AB.” … “Power was











We agree that the lack of precise clinical information is a limitation of our study.  We have
expanded our discussion of this limitation by adding the following sentence: 
 
“We could not identify the specific pathogens responsible for urinary infections, and we
lacked clinical data to confirm, classify and define the etiology of multifactorial disorders
(such as allergies and kidney disease).”
 
We have also expanded our discussion of the results for kidney disease and urinary
infections, citing evidence for uropathogenic E. coli and acute pyelonephritis.  Thank you
for this helpful suggestion. The revised paragraph now reads:
“Our study also provides new evidence that non-secretors may be predisposed to kidney
disease (RR, 1.39; 95% CI, 1.11–1.75), although we lacked clinical information to confirm
and classify this self-reported diagnosis. To our knowledge, the FUT2 genotype has not
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 and classify this self-reported diagnosis. To our knowledge, the FUT2 genotype has not
previously been associated with kidney disease in the general population, although some
studies have used traditional blood group assays to evaluate secretor status in patients
with pyelonephritis (kidney inflammation, typically due to bacterial infection).  One study
of women with acute uncomplicated pyelonephritis found that non-secretor status was
significantly higher in these patients than in the general population (Ishitoya et al. 2002),
and another found that renal scarring in girls with recurrent pyelonephritis was more
common in non-secretors than secretors . It has been hypothesized that these
associations reflect an increased susceptibility to uropathogenic Escherichia coli
infection among non-secretors, resulting from the enhanced expression of preferred
binding receptors in the vaginal epithelium and kidneys of non-secretor women
(Stapleton et al. 1992; Stapleton et al. 1998). Notably, in our study, the association
between FUT2 genotype and self-reported kidney disease appeared to be independent of
self-reported urinary infections. However, there are multiple clinically-distinct causes of
“kidney disease” and “urinary infections”, and we lacked clinical information to define the
etiology of these conditions in our study. Thus, additional research is needed to replicate
our observations with confirmed and clinically-defined kidney disease and urinary







Thank you for this suggestion. We considered correcting for multiple testing, but
ultimately decided against this because the conditions may not be independent of each
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